^
Association details:
| Biomarker: | NF2 mutation |
|---|---|
| Cancer: | Meningioma |
| Drug: | GSK2256098 (FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations
Published date:
10/26/2022
Excerpt:
Eligible patients whose tumors screened positively for NF2 mutations were treated with GSK2256098...Across all grades, one patient had a partial response and 24 had stable disease as their best response to treatment. In grade 1 patients, the observed PFS6 rate was 83% (10/12 patients; 95% CI, 52 to 98)....GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive NF2-mutated meningiomas...
DOI:
10.1200/JCO.21.02371
Trial ID:
